02:07:25 EDT Wed 22 May 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Rakovina Therapeutics Inc
Symbol RKV
Shares Issued 70,084,925
Close 2024-04-01 C$ 0.10
Market Cap C$ 7,008,493
Recent Sedar Documents

Rakovina hires Insight Capital for advisory services

2024-04-01 10:16 ET - News Release

Mr. David Hyman reports

RAKOVINA THERAPEUTICS TO HOST INFORMATIONAL WEBINAR ON APRIL 3, 2024

Rakovina Therapeutics Inc. will host an informational webinar on Wednesday, April 3, 2024.

The Rakovina leadership team and members of the scientific team will host the conference call to provide additional information about the company's recent announcement regarding its collaboration with the Deep Docking AI (artificial intelligence) platform and other industry insights.

Conference call details

Date:  April 3, 2024

Time:  10 a.m. Pacific Time (1 p.m. Eastern Time)

Rakovina Therapeutics has engaged the services of Insight Capital Partners Inc. (ICP) of Toronto to provide capital market advisory services to the company on a non-exclusive basis. These services include advising the company on financial market related initiatives, including access to ICP's automated market-making services through its proprietary algorithm, ICP Premium, in compliance with the policies and guidelines of the TSX Venture Exchange and other applicable legislation.

For the automated market-making services, ICP will receive a fee of $7,500 plus applicable taxes per month. The agreement between the company and ICP is for a term of three months and may continue on a month-to-month basis. There are no other compensation rights being granted in connection with the engagement. ICP and its clients may acquire an interest in the securities of the company in the future.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is focused on the development of new cancer treatments based on novel DNA damage response technologies. The company has established a pipeline of novel DNA damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the U.S. Food and Drug Administration, and similar international regulatory agencies.

© 2024 Canjex Publishing Ltd. All rights reserved.